HC Wainwright Reaffirms “Buy” Rating for Exelixis (NASDAQ:EXEL)

Exelixis (NASDAQ:EXEL – Get Free Report)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research report issued on Monday,Benzinga reports. They presently have a $40.00 price target on the biotechnology company’s stock. HC Wainwright’s price objective points to a potential upside of 23.53% from the company’s current price. Several […]

Leave a Reply

Your email address will not be published.

Previous post 1,027 Shares in Vanguard Mid-Cap Growth ETF (NYSEARCA:VOT) Acquired by Cathy Pareto & Associates Inc.
Next post ETF Portfolio Partners Inc. Reduces Stock Holdings in Vanguard Total World Stock ETF (NYSEARCA:VT)